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MicroRNAs (miRNAs) may be important regulators of gene expression. By modulating oncogenic 
and tumor suppressor pathways they could, in principle, contribute to tumorigenesis. Consistent 
with this hypothesis, recurrent genetic and epigenetic alterations of individual miRNAs are found 
in some tumors. Functional studies are now elucidating the mechanism of action of putative onco-
genic and tumor suppressor miRNAs.Sixteen years ago in back-to-back 
papers in Cell, Ambros, Ruvkun, and 
their colleagues reported that a small 
RNA encoded by the lin-4 locus con-
trols the developmental timing of the 
nematode Caenorhabditis elegans 
by modulating the expression of the 
protein-coding gene lin-14 (Lee et al., 
1993; Wightman et al., 1993). At the 
time, few would have imagined that 
this discovery marked the birth of a 
new and far-reaching field of research. 
Indeed, it took several more years to 
appreciate that small RNAs like lin-4 
(now termed microRNAs or miRNAs) 
were not just an interesting peculiarity 
of the nematode but were an abundant 
(and pervasive) feature of all Bilateria, 
including Homo sapiens (reviewed in 
Bartel, 2004).
More recently, biochemical and 
genetic studies have begun to reveal 
the physiological functions of individual 
miRNAs. We now know that miRNAs 
act by modulating the expression of 
target genes through sequence com-
plementarity between the so-called 
“seed” sequence of the miRNA and 
the “seed-match” present in the target 
messenger RNA (mRNA). Such bind-
ing inhibits the translation and reduces 
the stability of the mRNA, leading to 
decreased expression of the target pro-
tein. MicroRNAs control a wide array of 
biological processes, including differ-
entiation, proliferation, and apoptosis. 
As the deregulation of these very same 
processes is a hallmark of cancer, there 586 Cell 136, February 20, 2009 ©2009 Elsehas been speculation that mutations 
affecting miRNAs or their functional 
interactions with oncogenes and tumor 
suppressor genes might also contribute 
to tumorigenesis. Here, we summarize 
recent findings that now strongly sup-
port an important role for these tiny 
RNAs in controlling cell transformation 
and tumor progression. 
A Plethora of Possible Oncogenic 
Mechanisms
Because miRNAs act by repressing gene 
expression through direct base-pairing 
interactions with their target mRNAs, 
there are several possible mechanisms 
through which miRNAs could affect tum-
origenesis. Overexpression, amplifica-
tion, or loss of epigenetic silencing of a 
gene encoding an miRNA that targets 
one or more tumor suppressor genes 
could inhibit the activity of an anti-onco-
genic pathway. By contrast, the physi-
cal deletion or epigenetic silencing of an 
miRNA that normally represses expres-
sion of one or more oncogenes might 
lead to increased protein expression and 
a gain of oncogenic potency. More subtle 
mutations affecting the sequence of the 
mature miRNA could reduce or eliminate 
binding to key targets or even drastically 
change its specificity, thereby altering 
the balance of critical growth regula-
tory proteins. Seed-match sequences of 
target mRNAs could also be the sites of 
mutation, rendering them free from the 
repression of a given miRNA or subject 
to the effects of another (Table 1).vier Inc.Although only some of these potential 
mechanisms have been documented in 
human cancers, over the past 6 years 
a veritable flood of reports have linked 
miRNAs to tumor development in one 
fashion or another. These range from 
the identification of genomic and gene 
expression alterations affecting miRNA 
genes in human cancers to studies in 
genetically engineered mouse models 
of the disease. Taken together, the avail-
able data provide a compelling case that 
alterations in miRNA-mRNA regulation 
can promote tumor development.
As is true for protein-coding genes 
associated with cancer, the most con-
vincing evidence linking miRNAs to tum-
origenesis comes from genetic altera-
tions in cancer cells. Beginning with the 
work of Carlo Croce and colleagues in 
2002, who showed that a pair of neigh-
boring miRNAs are frequently deleted 
in human chronic lymphocytic leukemia 
(CLL), there are now additional examples 
in which miRNA genes are either lost or 
amplified in tumors (reviewed in Calin 
and Croce, 2006). Moreover, miRNA 
expression profiling studies compar-
ing cancer tissue to normal tissue have 
revealed provocative patterns of miRNA 
expression (such as the recurrent over-
expression or downregulation of individ-
ual miRNAs), some of which have been 
linked to changes in the methylation sta-
tus of miRNA genes (reviewed in Saito 
and Jones, 2006). Functional studies 
performed in cancer cell lines or mouse 
models of the disease have provided fur-
Table 1. MicroRNAs and Cancer
Mutation/Epigenetic Change Predicted Functional Consequence Examples
Deletion of miRNA Derepression of oncogene miR-15a-16-1
Epigenetic silencing of miRNA locus Derepression of oncogene miR-29, miR-203
Point mutation affecting an miRNA or an miRNA precursor Reduced affinity for oncogene N.E.
Increased affinity for tumor suppressor gene N.E.
Reduced processing efficiency miR-15a~16-1* 
Increased processing efficiency N.E.
Genomic amplification or translocation of miRNA locus Increased repression of tumor suppressor gene miR-17~92, miR-21
Loss of epigenetic silencing of miRNA locus Increased repression of target tumor suppressor gene N.E.
Point mutation in oncogene Decreased or lost affinity for miRNA N.E.
Point mutation in tumor suppressor gene Gain or increased affinity for miRNA N.E.
Rearrangement of 3′UTR (translocation, deletion) Loss of miRNA-mediated repression HMGA-2
Gain of miRNA-mediated repression N.E.
Shown are potentially oncogenic genetic and epigenetic changes involving miRNAs or their targets. The table includes changes affecting the miRNA 
gene directly as well as genetic lesions in protein-coding oncogenes and tumor suppressor genes that result in reduced or increased affinity for 
one or more miRNAs. (N.E., no known examples; *, the mutation is a single base change in pri-miR-15a~16-1, immediately downstream of the pre-
miR-16-1 sequence, and the sequence of the mature miRNA is not affected.)ther support for a direct role of a subset 
of these miRNAs in tumorigenesis. Simi-
lar to the miRNA field as a whole, the dis-
covery of the physiologically relevant tar-
gets of these cancer-associated miRNAs 
is still lagging, but here too, there has 
been recent progress with interesting 
candidate targets emerging.
MicroRNAs as Oncogenes
MicroRNAs that are amplified or over-
expressed in cancer could act as onco-
genes, and a number of putative onco-
genic miRNAs have been proposed (for 
a recent review see Medina and Slack, 
2008). An interesting case is represented 
by miR-155, which is upregulated in sev-
eral hematopoietic malignancies and 
tumors of the breast, lung, and pancreas 
(reviewed in Kluiver et al., 2006). The 
gene encoding the primary transcript for 
miR-155 had been identified well before 
the discovery of miRNAs, as a common 
proviral DNA insertion site in lympho-
mas induced by the avian leukosis virus. 
The absence of an obvious open read-
ing frame remained a puzzling feature 
of the BIC oncogene (as it was initially 
named) even after it was shown that it 
could cooperate with Myc in inducing 
hematopoietic tumors. Although the 
observation that the BIC RNA can form 
extensive secondary structures (includ-
ing a 145 base pair stem loop that we 
now know is the precursor to miR-155) 
suggested that the RNA itself could be 
the oncogenic factor (Tam et al., 1997), its mechanism of action remained unclear 
until the identification of miR-155. The 
study of genetically engineered mice 
with gain- and loss-of-function alleles 
of miR-155 has provided valuable 
insights into its physiological and onco-
genic properties. Ectopic expression of 
miR-155 in the bone marrow of mice has 
been reported to induce either polyclonal 
pre-B cell proliferation followed by full-
blown B cell leukemia (Costinean et al., 
2006) or myeloproliferation (O’Connell et 
al., 2008), depending on the system used 
to drive expression of the transgene.
Although miR-155 is dispensable for 
normal B and T cell development, miR-
155-deficient mice have defective B and 
T cells (Rodriguez et al., 2007; Thai et al., 
2007; Vigorito et al., 2007). In particular, 
these mice display a reduced germinal 
center B cell reaction and defective IgG 
production in response to immunization 
with either T cell-dependent or -indepen-
dent antigens (IgM production is normal). 
These results suggest an important role 
for miR-155 in the generation of isotype-
switched, high-affinity antibodies. Among 
the several targets of miR-155 that may 
mediate its function is the gene encoding 
activation-induced cytidine deaminase 
(AID), which allows immunoglobulin diver-
sification by promoting somatic hyper-
mutation and class-switch recombina-
tion in B cells. Two groups have recently 
demonstrated that mutation of the single 
miR-155 binding site in the 3′ untranslated 
region (3′UTR) of the AID gene partially Cell 136, phenocopies deletion of miR-155 itself 
(Dorsett et al., 2008; Teng et al., 2008). 
In both cases, the result is increased lev-
els of AID in germinal center B cells and 
impaired affinity maturation in response 
to antigen stimulation, but the phenotypic 
overlap is only partial. Although class-
switch recombination is reduced in mice 
lacking miR-155 (Thai et al., 2007; Vigorito 
et al., 2007), it is increased in mice car-
rying mutant AID (Dorsett et al., 2008; 
Teng et al., 2008). Thus, although these 
experiments elegantly demonstrate how 
loss of miRNA-mediated regulation of 
a single target gene can have profound 
physiological effects, they also serve as 
a reminder that the phenotypic conse-
quences of loss of an miRNA are likely 
due to the simultaneous deregulation of 
many target genes.
Another notable member of the family 
of oncogenic miRNAs is the miR-17~92 
cluster (reviewed in Mendell, 2008). This 
cluster, which consists of six miRNAs 
that are processed from a single primary 
transcript, was initially linked to cancer 
based on the observation that it maps to 
a chromosomal region that is frequently 
amplified in a subset of human B cell 
lymphomas (Ota et al., 2004) and overex-
pressed in a variety of other human can-
cers. In an important in vivo test of the 
oncogenic potential of miR-17~92, He et 
al. (2005) demonstrated that a truncated 
version of the cluster (lacking the most 
distal miRNA, miR-92) could cooperate 
with c-Myc and greatly accelerate tum-February 20, 2009 ©2009 Elsevier Inc. 587
origenesis in a mouse model of B cell 
lymphoma. Although miR-17~92 deregu-
lation does not appear to be sufficient 
to initiate tumorigenesis per se, trans-
genic mice overexpressing this cluster 
in lymphocyte progenitor cells develop 
a lymphoproliferative disorder affecting 
both B and T cells that eventually results 
in autoimmunity (Xiao et al., 2008). In 
contrast, mice carrying a homozygous 
deletion of the miR-17~92 locus exhibit 
premature death of B cells at the pro-B/
pre-B stage resulting in lymphopenia 
(Ventura et al., 2008).
Although the full spectrum of genes 
regulated by the miR-17~92 cluster is still 
unknown, one candidate, the pro-apop-
totic gene Bim, could be a likely media-
tor of the B cell phenotype in miR-17~92 
null mice and in miR-17~92 transgenic 
mice (Ventura et al., 2008; Xiao et al., 
2008). Bim is a critical regulator of B cell 
survival and a potent tumor suppressor 
gene in the Eµ-Myc model of B cell lym-
phoma (Egle et al., 2004). Its 3′UTR con-
tains multiple binding sites for miRNAs 
encoded by miR-17~92. Consistent with 
Bim being a direct target of miR-17~92, 
its expression is increased in miR-17~92 
null pre-B cells and reduced in B cells 
from mice overexpressing miR-17~92. It 
is therefore likely that Bim suppression 
by miR-17~92 contributes to both the 
tumor-promoting activity of miR-17~92 
overexpression and its physiologi-
cal function in regulating normal B cell 
development.
The analysis of mice lacking miR-17~92 
is also shedding light on additional 
functions of this cluster (Ventura et al., 
2008). Mice lacking miR-17~92 are much 
smaller than their wild-type littermates, 
have severely hypoplastic lungs, have 
an incompletely closed interventricular 
septum, and die within a few minutes 
after birth. The lung hypoplasia is of par-
ticular interest, as miR-17~92 overexpres-
sion, and occasionally amplification of 
the locus, has been reported in human 
lung cancers (Hayashita et al., 2005). The 
mechanism underlying the lung hypopla-
sia is currently unclear, but reduced cell 
proliferation may play a role. Consistent 
with this hypothesis, forced expression 
of miR-17~92 under the control of a lung-
specific promoter leads to increased pro-
liferation and blocks differentiation of the 
lung epithelium in vivo (Lu et al., 2007).588 Cell 136, February 20, 2009 ©2009 ElseMicroRNAs as Tumor Suppressors
Several miRNAs have been implicated 
as tumor suppressors based on their 
physical deletion or reduced expression 
in human cancer. Beyond these associa-
tions, functional studies of a subset of 
these miRNAs indicate that their overex-
pression can limit cancer cell growth or 
induce apoptosis in cell culture or upon 
transplantation in suitable host animals. 
This increasingly long list includes at 
least a dozen miRNAs and miRNA clus-
ters (Medina and Slack, 2008), but we 
will discuss only a few representative 
examples here.
The miR-15a~16-1 cluster of miRNAs 
has recently emerged as an excellent 
candidate for the long sought-after tumor 
suppressor gene on 13q14. This chro-
mosomal region is deleted in the major-
ity of CLLs and in a subset of mantle cell 
lymphomas and prostate cancers (Calin 
et al., 2002). There is strong circumstan-
tial evidence that miR-15a~miR-16-1 
is a bona fide tumor suppressor. miR-
15a~16-1 is located in the minimally 
deleted region in CLL (Calin et al., 2002), 
and a germline point mutation (a single 
base change) immediately downstream 
of the pre-miR-16-1 sequence has been 
observed in a few CLL patients (Calin et 
al., 2005). This mutation has been linked 
to reduced expression of miR-16-1, pos-
sibly due to less efficient processing of 
the precursor RNA, but large-scale stud-
ies are needed to determine whether 
this is indeed a cancer-predisposing 
mutation. Interestingly, in New Zealand 
Black mice, a strain that shows a strong 
predisposition to developing a B cell 
lymphoproliferative disease reminiscent 
of human CLL, a similar base change 
in pre-miR-16-1 is associated with the 
development of this lymphoproliferative 
disease (Raveche et al., 2007).
The tumor suppressor activity of miR-
15a~16-1 is not limited to B cells. More 
than 50% of human prostate cancers 
carry a deletion of 13q14. Accordingly, 
a recent study has shown that inhibi-
tion of miR-15a and miR-16 activity 
leads to hyperplasia of the prostate in 
mice and promotes survival, prolifera-
tion, and invasion of primary prostate 
cells in vitro (Bonci et al., 2008). In the 
same study, the therapeutic potential of 
reconstituting expression of this cluster 
was illustrated by the significant regres-vier Inc.sion of prostate tumor xenografts upon 
intra-tumoral delivery of miR-15a and 
miR-16-1. Although the identity of the 
critical targets of these two miRNAs is 
still unknown, the list of oncogenes that 
are directly regulated by miR-15a and 
miR-16-1 include BCL2, cyclin D1, and 
WNT3A.
Among the most actively studied of 
the putative tumor suppressor miRNAs 
are the members of the let-7 family 
(reviewed in Roush and Slack, 2008). The 
human genome contains a dozen let-7 
family members, organized in eight dif-
ferent loci (http://microrna.sanger.ac.uk/
sequences/mirna_summary.pl?fam = 
MIPF0000002). The first member of the 
let-7 family was discovered in C. elegans, 
where it induces cell-cycle exit and ter-
minal differentiation of a particular cell 
type at the transition from larval to adult 
life. Consistent with a role in inhibiting 
tumor development in humans, reduced 
expression of multiple members of the 
let-7 family is frequently observed in lung 
cancers, where they correlate with poor 
prognosis (Yanaihara et al., 2006). In 
addition, various let-7 genes are located 
at chromosomal sites deleted in a vari-
ety of human cancers. Let-7 genes can 
also be directly repressed by the c-Myc 
oncoprotein (Chang et al., 2008) and 
their precursor RNAs subjected to inhi-
bition of further processing by lin-28 
(Newman et al., 2008; Viswanathan et 
al., 2008). Functionally, let-7 represses 
members of the Ras family of oncogenes 
(Johnson et al., 2005) as well as the 
oncogene HMGA2 (Lee and Dutta, 2007; 
Mayr et al., 2007) and even c-Myc itself 
(Sampson et al., 2007). In the best exam-
ple of an oncogenic mutation affecting 
an miRNA-binding site, translocations 
involving the HMGA2 oncogene remove 
functional let-7 seed-match sequences, 
causing overexpression of the oncopro-
tein (Lee and Dutta, 2007; Mayr et al., 
2007). Finally, overexpression of let-7 
miRNAs can suppress tumor develop-
ment in mouse models of breast and 
lung cancer (Kumar et al., 2008; Yu et al., 
2007). Mouse knockout studies have not 
been reported for any let-7 family mem-
bers, and, given the potential for func-
tional overlap within this family, it may 
be some time before it is clear whether 
loss of let-7 in the mouse can promote 
tumorigenesis.
Recent studies have explored the reg-
ulation of miRNAs by tumor suppressor 
genes. These studies have focused on 
the miRNAs regulated by p53, a tumor 
suppressor gene that is frequently inac-
tivated in human cancers (reviewed in 
He et al., 2007 and references therein). 
This approach has lead to the identifica-
tion of the miR-34 family as an impor-
tant mediator of p53 activity. This family 
consists of three highly related miRNAs 
expressed from two separate loci: miR-
34a from chromosome 1p36 and the 
miR-34b/miR-34c cluster from chromo-
some 11q23. The transcription of both 
loci appears to be directly regulated by 
p53 through binding to conserved sites 
in the respective promoters. Similar to 
p53 itself, the expression of miR-34 
can induce cell-cycle arrest or apopto-
sis. Reduced expression of miR-34b/
miR-34c has been reported in breast 
and non-small cell lung cancer cell lines. 
Furthermore, miR-34a is located on 
1p36, a region of frequent hemizygous 
deletion in human neuroblastomas and 
a variety of other cancers. Interestingly, 
this region includes another candidate 
tumor suppressor gene, CDH5, that acts 
by inducing p53 expression via p19Arf. 
Thus, a deletion of 1p36 can impair the 
p53 pathway simultaneously upstream 
and downstream of p53.
MicroRNAs as Modulators of Tumor 
Progression and Metastasis
In addition to their role in promoting the 
development of primary tumors, miRNAs 
have also been implicated in affecting 
tumor progression, including the lethal 
metastatic phase of the disease. Sev-
eral cell biological processes, including 
those controlling adhesion, migration, 
and invasion, are involved in allowing 
primary tumor cells to leave their original 
locations and to move to another site in 
the body. Not surprisingly, miRNAs help 
to regulate these processes, and altera-
tions in miRNA function can influence 
metastatic potential (reviewed in Ma and 
Weinberg, 2008 and referenced therein).
Among several putative prometa-
static miRNAs, miR-10b and miR-373 
are of particular interest. The miR-10b 
miRNA is a direct transcriptional target 
of Twist1, a known inducer of the epi-
thelial-to-mesenchymal transition (EMT) 
and metastatic progression. Ectopic expression of miR-10b in nonmetastatic 
breast cancer cell lines promotes cellular 
invasiveness and the metastatic spread 
of transplanted tumors, at least in part 
as a consequence of the direct repres-
sion of the homeobox protein HOXD10. 
The miR-373 miRNA was identified in a 
functional screen for miRNAs that could 
promote cell migration in vitro (Huang et 
al., 2008), and its prometastatic potential 
has been validated in tumor transplan-
tation experiments using breast cancer 
cells. Of note, miR-373 has been iden-
tified as a potential oncogene (together 
with miR-372) in testicular germ cell 
tumors (Voorhoeve et al., 2006). How-
ever, it has been proposed that the pro-
metastatic and oncogenic properties 
of this miRNA are due to the regulation 
of different genes (encoding CD44 and 
LATS2, respectively).
Studies of breast cancers have also 
revealed a series of miRNAs that are 
both underexpressed in advanced can-
cers and capable of inhibiting cell migra-
tion and metastatic spread. Members of 
the miR-200 family of miRNAs target the 
ZEB transcription factors, known induc-
ers of the EMT, and thus reduce cellu-
lar migration and invasiveness (Gregory 
et al., 2008; Park et al., 2008). Based 
on their differential expression in non-
metastatic versus metastatic breast 
cancer cell lines, miR-126, miR-206, 
and miR-335 were also proposed to be 
inhibitors of tumor progression (Tavazoie 
et al., 2008). Indeed, overexpression of 
these miRNAs can inhibit metastasis in a 
cell transplantation model, and reduced 
expression of miR-126 and miR-335 cor-
relates with poor metastasis-free sur-
vival of breast cancer patients (Tavazoie 
et al., 2008).
Global Deregulation of MicroRNAs 
in Cancer
We have focused on the role of specific 
miRNAs in tumorigenesis, an already 
extensive and rapidly expanding list. 
However, recent work has also revealed 
intriguing changes in the global state of 
miRNA expression in cancer. Specifi-
cally, miRNA expression profiling experi-
ments have demonstrated that most 
(although not all) miRNAs are underex-
pressed in tumor tissues compared to 
normal tissues (Lu et al., 2005). Although 
it is possible that this phenomenon Cell 136,reflects the less differentiated states of 
the tumor cells or their higher prolifera-
tion rates, one alternative explanation is 
that reduced miRNA levels are selected 
during tumorigenesis because this itself 
provides some proliferative or survival 
advantage. These two possibilities are 
not necessarily mutually exclusive and 
indeed there is experimental evidence 
for both. For example, a significant 
increase in miRNA levels is observed 
upon induction of differentiation of the 
cancer cell line HL60 (Lu et al., 2005), 
consistent with the ability of miRNAs to 
reinforce transcriptional programs and 
to help maintain the differentiated state. 
On the other hand, work with experimen-
tal models of lung cancer has shown 
that genetic or RNAi-based inhibition of 
miRNA biogenesis can promote tumor 
formation and progression (Kumar et al., 
2007). Finally, widespread transcriptional 
silencing of miRNAs by c-Myc (Chang et 
al., 2008) has been reported, suggesting 
a potential mechanism for the observed 
global downregulation of miRNAs in 
transformed cells.
Independent of the functional conse-
quences of miRNA expression patterns 
in cancer, miRNA profiles have value as 
diagnostic and prognostic markers of 
disease. For example, it is sometimes 
impossible to determine the tissue of 
origin of a metastatic tumor in patients 
with unknown primary tumors. Because 
many miRNAs display exquisite tissue 
specificity, miRNA profiling of these 
lesions might prove useful. The initial 
findings are encouraging, as it appears 
that miRNA-based classification is more 
efficient at identifying the tissue of origin 
of poorly differentiated cancers than is 
mRNA profiling (Lu et al., 2005; Rosen-
feld et al., 2008). MicroRNA profiling of 
human cancer might guide the choice of 
the best treatment strategy by providing 
prognostic information. Indeed, in the 
two most common forms of non-small 
cell lung cancers (adenocarcinomas 
and squamous cell carcinomas), high 
expression of miR-155 and low expres-
sion of let-7 correlate with poor progno-
sis (Yanaihara et al., 2006). Similarly, in 
colon cancers, elevated expression of 
miR-21 is associated with poor survival 
(Schetter et al., 2008), whereas in chronic 
lymphocytic leukemias an miRNA “signa-
ture” composed of 13 miRNAs is associ- February 20, 2009 ©2009 Elsevier Inc. 589
ated with disease progression (Calin et 
al., 2005). The results of these and other 
related reports are promising, but larger-
scale studies will be required to validate 
the usefulness of miRNA profiling in a 
clinical setting.
A View to the Future
Despite remarkable recent progress, the 
field of miRNAs and cancer is still in its 
infancy and many important questions 
remain to be addressed. Much of the evi-
dence for the existence of oncogenic and 
tumor suppressor miRNAs would be best 
characterized as “guilt by association.” 
With the exception of miR-155, which, 
as discussed above, can induce the for-
mation of B cell leukemia when ectopi-
cally expressed in mice, to date none 
of the putative oncogenic miRNAs have 
been shown to be sufficient to initiate 
neoplastic transformation on their own. 
Likewise, whereas many miRNAs may 
act as tumor suppressors based on their 
recurrent deletion or silencing in human 
cancers or on their growth suppressive 
properties in cell-based experiments, 
none has been subjected to germline 
loss-of-function analysis in mouse mod-
els. This absence of evidence should not 
be construed as evidence of absence, as 
it likely reflects the youth of the field as 
well as the complexity of gene targeting 
experiments involving multiple, function-
ally related genes. Similarly, although the 
identification and validation of miRNA 
targets proceeds at an increasing pace, 
we still know very little about the cellular 
circuits controlled by miRNAs in general 
and by cancer-associated miRNAs in 
particular. One should resist the tempta-
tion to expect that one or a few target 
mRNAs can fully explain the biological 
properties of a particular miRNA or, even 
less so, of an miRNA cluster. More likely, 
their effects will be found to be the net 
result of the complex modulation of mul-
tiple targets belonging to multiple path-
ways.
A clearer picture of the role of miRNAs 
in human cancer will likely emerge as the 
efforts to resequence the cancer genome 
reveal the true frequency of mutations in 
miRNAs and in their target sequences 
in protein-coding genes (although the 
latter will require specific analysis of 
the 3′UTR regions). At the same time, 
more sophisticated in vivo models will 590 Cell 136, February 20, 2009 ©2009 Elselikely help determine the oncogenic 
and tumor suppressor potential of indi-
vidual miRNAs and miRNA families. 
Also, improved experimental and com-
putational methods to identify miRNA 
targets will provide a more comprehen-
sive understanding of their mechanism 
of action and of the pathways that they 
modulate. It is difficult to overestimate 
the potential impact of these findings. 
As increasingly effective pharmacologi-
cal means to modulate miRNA activities 
are currently being developed (Elmen et 
al., 2008), identifying miRNAs that are 
essential for tumor maintenance or for 
metastasis might provide exciting new 
therapeutic opportunities. What began 
16 years ago as a peculiar discovery in 
the simple worm has already had a major 
impact on our understanding of gene 
regulation. Although not yet a hallmark 
of cancer, alterations in miRNA function 
and regulation have rapidly emerged as 
important players in cancer pathogen-
esis. Before long, they might influence 
how the disease is treated as well.
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